Joel Schneider
Director Ejecutivo en Carbon Biosciences, Inc. .
Perfil
Joel Schneider is currently the President & Chief Executive Officer at Carbon Biosciences, Inc. Prior to his current position, he served as the Chief Operating Officer at Solid Biosciences, Inc. from 2021 to 2022.
Dr. Schneider completed his undergraduate degree at Brandeis University in 2006 and obtained his doctorate from Rutgers State University of New Jersey in 2012.
Cargos activos de Joel Schneider
| Empresas | Cargo | Inicio |
|---|---|---|
Carbon Biosciences, Inc.
 Carbon Biosciences, Inc. Medical/Nursing ServicesHealth Services Carbon Biosciences, Inc. is a biotech company that is based in Boston, MA. The company is focused on expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues and carry a larger cargo with minimal neutralizing immunity and the potential to re-dose. The company is working to expand the gene therapy toolbox for the treatment of the world's most devastating and difficult to treat diseases. Carbon was founded by Longwood Fund and gene therapy pioneers, John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D. | Director Ejecutivo | - |
Antiguos cargos conocidos de Joel Schneider.
| Empresas | Cargo | Fin |
|---|---|---|
| SOLID BIOSCIENCES INC. | Director Técnico/Científico/I+D | 02/03/2021 |
Formación de Joel Schneider.
| Brandeis University | Undergraduate Degree |
| Rutgers State University of New Jersey | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| SOLID BIOSCIENCES INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Carbon Biosciences, Inc.
Carbon Biosciences, Inc. Medical/Nursing ServicesHealth Services Carbon Biosciences, Inc. is a biotech company that is based in Boston, MA. The company is focused on expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues and carry a larger cargo with minimal neutralizing immunity and the potential to re-dose. The company is working to expand the gene therapy toolbox for the treatment of the world's most devastating and difficult to treat diseases. Carbon was founded by Longwood Fund and gene therapy pioneers, John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D. | Health Services |
- Bolsa de valores
- Insiders
- Joel Schneider
